Clinical Trials

MainTitle

Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children

This study has been completed
Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)

Collaborator
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Information provided by (Responsible Party)
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier
NCT00312091

First received: April 5, 2006
Last updated: September 10, 2012
Last Verified: September 2012
History of Changes
Purpose

Purpose

The purpose of this study is to compare the blood levels, absorption, and breakdown of lamivudine (3TC), nevirapine (NVP), and stavudine (d4T) in a fixed-dose tablet to that of the individual liquid formulations of the same anti-HIV drugs in HIV infected Thai children.

Condition Intervention Phase
HIV Infections

Drug : Lamivudine, nevirapine, and stavudine fixed-dose tablet
Drug : Lamivudine
Drug : Nevirapine
Drug : Stavudine
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I/II Comparative Pharmacokinetic Study of the Fixed-Dose Combination (FDC) of Stavudine (d4T), Lamivudine (3TC), and Nevirapine (NVP) as GPO-VIR Pediatric Chewable Tablets Versus the Individual Liquid Formulations in HIV Infected Children 6 Months and Older to Less Than 13 Years of Age in Thailand

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures

  • Comparative bioavailability [ Time Frame: Throughout study ]
  • therapeutic adequacy [ Time Frame: Throughout study ]
Secondary Outcome Measures:
  • Drug absorption from standard pharmacokinetic (PK) analyses [ Time Frame: Throughout study ]

Enrollment: 44
Study Start Date: December 2006
Study Completion Date: September 2008
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)

Arms Assigned Interventions
Experimental: A, Stage 1
Tablet containing d4T, 3TC, and NVP taken orally twice daily for the first 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for the final 4 weeks
Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet

7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Other Name:
  • GPO-Vir
  • d4T/3TC/NVP

Drug: Lamivudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Nevirapine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Stavudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Experimental: A, Stage 2
Tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks
Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet

7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Other Name:
  • GPO-Vir
  • d4T/3TC/NVP

Drug: Lamivudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Nevirapine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Stavudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Experimental: B, Stage 1
Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 2 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 2 weeks
Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet

7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Other Name:
  • GPO-Vir
  • d4T/3TC/NVP

Drug: Lamivudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Nevirapine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Stavudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Experimental: B, Stage 2
Liquid formulations of d4T, 3TC, and NVP taken orally twice daily for 4 weeks, then tablet containing d4T, 3TC, and NVP taken orally twice daily for 4 weeks
Drug: Lamivudine, nevirapine, and stavudine fixed-dose tablet

7 mg d4T, 30 mg 3TC, 50 mg NVP tablet

Other Name:
  • GPO-Vir
  • d4T/3TC/NVP

Drug: Lamivudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Nevirapine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Drug: Stavudine

Dosage dependent on weight. More information on this criterion can be found in the protocol.

Detailed Description:

The Thai Ministry of Public Health strives to provide the HIV infected people of Thailand with affordable antiretrovirals (ARVs). A fixed-dose combination tablet of 3TC, NVP, and d4T is recommended as first-line treatment in HIV infected adults in Thailand. There has been no similar product developed for children for several reasons: pediatric dosing is based on age, weight, or body surface area; developmental changes may influence the bioavailability and pharmacokinetics (PK) of ARVs; and medication adherence may also be a problem. The purpose of this study is to gather bioavailability and PK data in children taking a fixed-dose tablet of 3TC, NVP, and d4T. This information will then be compared to the bioavailability and PK of the individual liquid formulations of these ARVs.
This study has two stages. Stage 1 will last a minimum of 4 weeks; Stage 2 will last a minimum of 8 weeks. In Stage 1, patients will be randomly assigned to one of two arms. Arm A will receive the fixed-dose tablet twice daily for 2 weeks, then switch to the individual liquid formulations twice daily for 2 weeks. Arm B will receive the individual liquid formulations twice daily for 2 weeks, then switch to the fixed-dose tablet twice daily for 2 weeks. To encourage medication adherence, study staff will make home visits and phone calls to each patient's parent or guardian the first week of each treatment regimen. Medical history, a physical exam, and urine collection will occur on Days 11 and 25. Also on Days 11 and 25, patients will be admitted to the hospital to ensure 100% medication adherence and to provide blood for PK studies.
Stage 1 patients are not eligible for Stage 2. In Stage 2, patients will be stratified by body weight, then randomly assigned to one of two arms. Arm A will receive the fixed-dose tablet twice daily for 4 weeks, then switch to the individual liquid formulations twice daily for 4 weeks. Arm B will receive the individual liquid formulations twice daily for 4 weeks, then switch to the fixed-dose tablet twice daily for 4 weeks. To encourage medication adherence, study staff will make home visits and phone calls to each patient's parent or guardian the first week of each treatment regimen. Medical history, documentation of direct observation of therapy (DOT), a physical exam, and urine collection will occur on Days 25 and

  1. Also on Days 25 and 53, patients will be admitted to the hospital to ensure 100%
medication adherence and to provide blood for PK studies.

Eligibility

Eligibility

Ages Eligible for Study: 6 Months to 13 Years  
Sexes Eligible for Study: All  
Accepts Healthy Volunteers: No  

Criteria

Inclusion Criteria for Stages 1 and 2:

  • HIV infected
  • On a highly active antiretroviral regimen (HAART) including NVP and 2 nucleoside reverse transcriptase inhibitors and receiving a maintenance of NVP for at least 4 weeks prior to study entry and taking the current recommended oral dose every 12 hours
  • Willing to swallow or chew study drugs
  • Willing to be hospitalized for the 12 hour PK studies
  • Willing to use acceptable forms of contraception
  • Parent or guardian willing to provide informed consent

  • Inclusion Criteria for Stage 1:
  • Between 12 to 30 kg (26.5 to 66.1 lbs)

  • Inclusion Criteria for Stage 2:
  • Between 6 to 30 kg (13.2 to 66.1 lbs)


Exclusion Criteria:
  • Certain abnormal laboratory values
  • Require certain medications
  • Grade 2 or greater vomiting within 30 days prior to study entry
  • Grade 2 or greater diarrhea within 30 days prior to study entry
  • History of immunological failure (CD4 percentage decrease of more than 30% within a 6-month period for children 6 years or younger OR CD4 cell count decrease of more than 30% within a 6-month period for children older than 6 years)
  • Current treatment for acute serious bacterial, viral, or opportunistic infection
  • History of dose-limiting toxicity requiring treatment discontinuation of any of the study drugs
  • Known hypersensitivity to any of the study drugs
  • Current surgical or medical problem affecting gastrointestinal motility or absorption (e.g., ileus, ulcerative colitis) or liver function
  • Treatment with immune modulators or myelosuppressive, neurotoxic, pancreatotoxic, hepatotoxic, or cytotoxic drugs within 30 days prior to study entry. Patients who have received therapeutic vaccines are not excluded.
  • Treatment with experimental drugs within 30 days of study entry
  • Acute inflammation of the liver
  • Chemotherapy for active cancer
  • Any clinically significant diseases other than HIV infection or clinically significant findings that, in the investigator's opinion, may interfere with the study
  • Inability to provide a reliable means of contact (e.g., telephone number)
  • Pregnancy

contacts and locations

Contacts and Locations

Choosing to participate in a study is an important personal decision.Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00312091

Locations

Thailand
Queen Sirikit National Institute of Child Health, Pediatric Infectious Unit
Bangkok, Ratchathewi, Thailand, 10400
Siriraj Hospital Mahidol University CRS
Bangkok, Ratchathewi, Thailand, 10700
Chiang Mai University Pediatrics-Obstetrics CRS
Chiang Mai, Thailand, 50200
Chonburi Hosp. CRS
Chonburri, Thailand, 20000 TH

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
International Maternal Pediatric Adolescent AIDS Clinical Trials Group

Investigators

Study Chair: Nirun Vanprapar, MD Pediatric Infectious Unit, Department of Pediatrics, Siriraj Hopstial, Mahidol University
More Information

More Information


Responsible Party: National Institute of Allergy and Infectious Diseases (NIAID)  
ClinicalTrials.gov Identifier: NCT00312091   History of Changes  
Other Study ID Numbers: P1056  
  10139  
  PACTG P1056  
  IMPAACT P1056  
Study First Received: April 5, 2006  
Last Updated: September 10, 2012  

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):

Pharmacokinetics
Treatment Experienced

Additional relevant MeSH terms:
HIV Infections
Lamivudine
Nevirapine
Stavudine

ClinicalTrials.gov processed this data on December 15, 2017
This information is provided by ClinicalTrials.gov.